Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–46 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Hypoplastic Left Heart, Congenital Heart Disease
Interventions
Oxandrolone
Drug
Lead sponsor
Carelon Research
Other
Eligibility
Up to 14 Days
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
9
States / cities
Atlanta, Georgia • Boston, Massachusetts • Ann Arbor, Michigan + 6 more
Conditions
Hypoplastic Left Heart Syndrome (HLHS)
Interventions
Collection of umbilical cord blood
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Female only
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
2
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania
Completed No phase listed Observational

NIRS in Neonatal Cardiac Surgery

NCT00166101
Conditions
Hypoplastic Left Heart, Surgery
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
1 Day to 1 Year
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Fontan Procedure, Hypoplastic Left Heart Syndrome, Tricuspid Atresia, Double Inlet Left Ventricle
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
10 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
San Francisco, California
Completed Phase 1Phase 2 Interventional Results available

Erythropoetin Neuroprotection for Neonatal Cardiac Surgery

NCT00513240
Conditions
Congenital Heart Disease, Hypoplastic Left Heart Syndrome, Transposition of the Great Arteries, Aortic Arch Hypoplasia or Interruption
Interventions
Erythropoetin, Normal saline
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Day to 30 Days
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Houston, Texas
Recruiting No phase listed Observational

The Co-Op @ HeartWorks

NCT06469918
Conditions
Congenital Heart Disease
Interventions
Not listed
Lead sponsor
HeartWorks, Inc.
Other
Eligibility
0 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2050
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Hypoplastic Left Heart Syndrome, Total Anomalous Pulmonary Venous Return, Truncus Arteriosus, Pulmonary Atresia With Ventricular Septal Defect, Transposition of the Great Arteries, Double Outlet Right Ventricle, Subpulmonary VSD, Tetralogy of Fallot, Double Outlet Right Ventricle With Subaortic Ventricular Septal Defect and Pulmonary Stenosis, Cardiopulmonary Bypass
Interventions
Normoxia (with controlled re-oxygenation), Standard of care ventilation
Other
Lead sponsor
University of Michigan
Other
Eligibility
Up to 29 Days
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Transposition of the Great Vessels, Hypoplastic Left Heart Syndrome, Oxygen Consumption Based Assessment of Hemodynamics
Interventions
General Electric Healthcare E-COVX Gas Monitoring Module for VO2 Measurments, Edwards Continuous SVO2 Catheter and Monitoring System - 4.5 fr
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Day to 6 Months
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Hypoplastic Left Heart Syndrome
Interventions
Lomecel-B medicinal signaling cells
Biological
Lead sponsor
Longeveron Inc.
Industry
Eligibility
Up to 12 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 6 more
Completed No phase listed Observational

Single Ventricle Outcome

NCT00308217
Conditions
Heart Disease, Congenital, Single Ventricle, Hypoplastic Left Heart Syndrome
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
HLHS
Interventions
Longeveron Mesenchymal Stem Cells
Biological
Lead sponsor
Longeveron Inc.
Industry
Eligibility
1 Day to 1 Year
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
5
States / cities
Atlanta, Georgia • Baltimore, Maryland • Cincinnati, Ohio + 1 more
Conditions
Hypoplastic Left Heart Syndrome
Interventions
Not listed
Lead sponsor
Timothy J Nelson, MD, PhD
Other
Eligibility
0 Months to 18 Months
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
3
States / cities
Rochester, Minnesota • Oklahoma City, Oklahoma • Philadelphia, Pennsylvania
Conditions
Congenital Heart Disease
Interventions
passive range of motion exercise therapy
Other
Lead sponsor
Carelon Research
Other
Eligibility
Up to 35 Days
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Boston, Massachusetts + 6 more
Conditions
Fontan Procedure, Hypoplastic Left Heart Syndrome, Tricuspid Atresia
Interventions
Vitamin C, Placebo
Dietary Supplement
Lead sponsor
University of Michigan
Other
Eligibility
8 Years to 25 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Heart Defects, Congenital
Interventions
Liothyronine sodium/triiodothyronine, Cardiopulmonary bypass and cardiac surgery
Drug · Procedure
Lead sponsor
Michael Portman
Other
Eligibility
Up to 2 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Hypoplastic Left Heart Syndrome, Atrioventricular Canal
Interventions
MPC; rexlemestrocel-L
Biological
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 5 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
HLH - Hypoplastic Left Heart Syndrome, DORV, DILV - Double Inlet Left Ventricle, Mitral Atresia, Tricuspid Atresia, Unbalanced AV Canal, Single-ventricle, Heart Defects, Congenital, Cardiovascular Abnormalities, Cardiovascular Diseases, Heart Diseases
Interventions
Tissue Engineered Vascular Grafts
Combination Product
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Hypoplastic Left Heart Syndrome (HLHS)
Interventions
Collaborative Learning Network
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 15 Months
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 53 more
Completed Phase 2 Interventional Results available

Ambrisentan in Single Ventricle

NCT02080637
Conditions
Hypoplastic Left Heart Syndrome, Hypoplastic Right-sided Heart Complex
Interventions
Ambrisentan, Placebo
Drug · Other
Lead sponsor
Kevin Hill
Other
Eligibility
24 Months to 120 Months
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Congenital Heart Disease, SRV Dependent
Interventions
Autologous mononuclear cells
Biological
Lead sponsor
Timothy J Nelson, MD, PhD
Other
Eligibility
2 Years to 5 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 3 more
Conditions
Single Ventricle Defect
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
4 Months to 10 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Tetrology of Fallot, Heart Ventricle, Hypoplastic Left Heart
Interventions
Dexmedetomidine
Drug
Lead sponsor
Athena Zuppa
Other
Eligibility
1 Hour to 30 Days
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania